Intra-Cellular Therapies Inc

-2.28 (-4.22%)
6:45:23 PM EDT: $53.00 +1.19 (+2.30%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.91B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$85.9 Million
Adjusted EPS-$0.60
See more estimates
10-Day MA$52.77
50-Day MA$49.55
200-Day MA$53.72
See more pivots

Intra-Cellular Therapies Inc Stock, NASDAQ:ITCI

430 East 29th Street, Suite 900, New York, New York 10016
United States of America
Phone: +1.464.440.9333
Number of Employees: 512


Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firmâ??s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.